We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Faricimab for neovascular agerelated macular degeneration and diabetic macular oedema.
- Abstract
Faricimab is a new drug approved for the treatment of neovascular age-related macular degeneration (AMD) and diabetic macular edema. It is the first bispecific monoclonal antibody for intraocular use. Faricimab inhibits pathological angiogenesis and reduces vascular permeability and inflammation in the eye. Clinical trials have shown that faricimab is noninferior to aflibercept, another VEGF inhibitor, in improving visual acuity in patients with AMD and diabetic macular edema. The drug has a similar safety profile to aflibercept, with mild to moderate ocular adverse events being the most commonly reported. Faricimab has the potential to extend treatment intervals, reducing the burden on patients.
- Subjects
DIABETIC retinopathy; MACULAR degeneration; MACULAR edema; VASCULAR endothelial growth factor receptors
- Publication
Australian Prescriber, 2024, Vol 47, Issue 2, p66
- ISSN
0312-8008
- Publication type
Article
- DOI
10.18773/austprescr.2024.013